The CDC estimates 2.2 million Americans could benefit from HIV prevention drugs, but just over a quarter of that group have ...

Taken as prescribed, PrEP — shorthand for preexposure prophylaxis — is 99% effective in protecting people against sexual ...

Gilead Sciences’ pre-exposure prophylaxis (PrEP) formula of lenacapavir has been approved in the UK as a preventative option for HIV, offering patients a twice-yearly injection to reduce the risk of ...

The U.S. Food and Drug Administration has approved a highly effective HIV prevention drug that outperforms oral medications in stopping HIV transmission. Developed by Gilead Sciences, the drug ...

A twice-a-year injectable drug has been shown to be 100% effective in preventing the spread of HIV, according to the first data from a clinical trial. If approved, the drug offers another preventive ...

It’s possible to produce a generic version of lenacapavir, a twice-yearly antiretroviral injection that both prevents and treats HIV, for as little as $25 per patient per year, according to a study ...

A clinical trial underway in South Africa and Uganda has shown that a twice-yearly injection of a new PrEP drug gives young women total protection from HIV infection, according to a July 10 report at ...

ATLANTA — Five years ago, the U.S. government unveiled a plan to end the HIV epidemic by 2030. More than 30,000 people are diagnosed with HIV every year in this country. But this is not a problem for ...

HIV rates are up in Atlanta. Activists and Georgia politicians say this doesn’t have to happen because cheap and safe medicines known as PrEP are over 99% effective at blocking the infection when ...

In June, Gilead Sciences announced impressive early results from its PURPOSE 1 trial, which showed 100 percent efficacy of lenacapavir in preventing new HIV infections among cisgender women in ...

Kenya has taken a major step towards expanding HIV prevention options after the Ministry of Health formally recommended the ...

New Trump administration rules on foreign assistance are prohibiting U.S.-backed programs from delivering HIV prevention drugs to large swaths of the at-risk population abroad, according to what ...